Funding
Seed · Biotech

SRTD Biotech secures initial seed financing led by HTGF

The November 2024 financing supported development of cell-selective RNA therapies.

By RoundOS Funding desk

SRTD Biotech completed a seven-figure seed financing led by High-Tech Gründerfonds, with participation from business angels, according to a November 14, 2024 announcement. An exact amount was not disclosed.

The Jülich company planned to use the capital to develop RNA therapeutics that activate selectively inside diseased cells. Its initial work focused on liver cancer, with a modular platform intended to support other cancer and autoimmune applications.

Use of funds

Develop selectively expressed RNA therapies

Funding history

Seed · This roundUndisclosed

Sources

  1. SRTD Biotech financinghtgf.de · Nov 14, 2024

Similar rounds

All Biotech rounds →
Sunlit Seedlings

Sunlit Seedlings measures biodiversity and microbial activity to help organisations assess and redesign ecosystems.

UndisclosedCorporate investment · Nov 13, 2026
Biomatter

Biomatter designs custom enzymes for pharmaceutical, diagnostic, agricultural and industrial applications.

$18MSeries A · Nov 12, 2026
TOKI Fund I

TOKI Fund I backs Japanese seed-stage startups, with a focus on advanced medicine and content.

UndisclosedLP commitment · Nov 12, 2026

Related